Maine drug disposal bill dies
This article was originally published in The Tan Sheet
The Maine Senate indefinitely postpones legislation passed by the House that would have impelled manufacturers to contribute to an "Unused Pharmaceutical Disposal Program Fund." The Senate placed LD 821 in legislative files March 26, effectively killing it. The Consumer Healthcare Products Association opposed the bill and favors consumer education on safe drug disposal (1"The Tan Sheet" March 22, 2010, In Brief)
You may also be interested in...
The Consumer Healthcare Products Association opposes a bill approved by Maine's House of Representatives that would require drug manufacturers to fund a system for disposing of unwanted Rx and OTC drugs. A CHPA spokeswoman said the trade group instead supports consumers using "more effective means of ensuring safe medicine disposal which not only protect the environment, but also prevent illegitimate access to drugs, decrease potential abuse and limit accidental poisonings." CHPA backs the SMARxT Disposal campaign, which educates consumers on proper disposal of unwanted medicines and which the American Pharmacists Association supports. The bill received a 91-51 vote March 17 and moves next to the Senate
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.